Tesla Recalls Model...
Health Care: Drugs
Apricus Biosciences Inc. (APRI: NASDAQ)
$2.54 -0.03 | -1.17%
06/19/13 - 03:20 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -31.77M | -18.12M | -29.51M | -32.04M |
| Operating Gains/Losses | -250.00K | 2.76M | 2.04K | -31.34K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 657.00K | 318.87K | 607.91K | -570.75K |
| (Increase) Decrease in Inventories | 0.00 | -342.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | 690.00K | 1.02M | -737.85K | -686.43K |
| (Decrease) Increase In Other Current Liabilities | -381.00K | 1.30M | 81.39K | 173.80K |
| (Increase) Decrease In Other Working Capital | -507.00K | -79.16K | 285.86K | -74.16K |
| Other Non-Cash Items | 18.38M | 2.74M | 12.71M | 902.67K |
| Net Cash From Continuing Operations | -12.62M | -9.72M | -6.89M | -3.51M |
| Net Cash From Discontinued Operations | -2.08M | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -14.70M | -9.72M | -6.89M | -3.51M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 1.39K | 350.00K |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -436.00K | -262.75K | -436.96K | -5.53K |
| Acquisitions | 1.80M | 107.17K | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 300.00K | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | 1.37M | -155.58K | -435.57K | 344.47K |
| Issuance of Debt | 0.00 | 0.00 | 6.59M | 686.68K |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 20.46M | 6.17M | 12.60M | 0.00 |
| Repayment of Long-Term Debt | -4.00M | -416.91K | -3.20M | -50.60K |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 4.32M | 2.42M | 0.00 | 0.00 |
| Net Cash From Financing Activities | 20.78M | 8.17M | 15.99M | 636.08K |
| Effect of Exchange Rate Changes | 243.00K | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | 7.70M | -1.71M | 8.67M | -2.53M |
Portfolios with APRI
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
Latest APRI Headlines from TheStreet
- Apricus Biosciences To Present At 2013 BIO International Convention 04.18.13 | 07:04 am
- Apricus Biosciences Announces Sale Of Non-Core Assets 04.01.13 | 04:04 pm
- Apricus Biosciences Provides Corporate Update; Files Annual Report For Quarter And Year Ended December 31, 2012 03.18.13 | 11:03 am
- Apricus Biosciences Appoints Richard W. Pascoe As Chief Executive Officer 03.18.13 | 11:03 am
- Apricus Biosciences Announces 2012 Year End Financial Results Conference Call 03.14.13 | 09:03 am
- Apricus Biosciences Announces Ceasing Of Financing Of French Subsidiaries 03.14.13 | 08:03 am
- Apricus Biosciences To Present At The 25th Annual ROTH Conference 03.13.13 | 04:03 pm
- Apricus Biosciences To Present At BIO-Europe Spring 2013 03.07.13 | 08:03 am
- Apricus Biosciences To Present At The 15th Annual BIO CEO & Investor Conference 02.06.13 | 08:02 am
- 5 Stocks Poised for Breakouts 02.01.13 | 01:02 pm
Press Releases for APRI
- Apricus Biosciences, Inc. (APRI) Transforms From Development Company To Income Generating! - PR Newswire 03.14.12 | 09:03 am
- Apricus Biosciences To File For Market Authorization To Sell Vitaros® For Erectile Dysfunction In Latin America - PR Newswire 08.08.11 | 07:08 pm
- Apricus Biosciences Launches Educational Video Series Focused On Its Newly Approved Erectile Dysfunction Drug, Vitaros® - Business Wire 12.06.10 | 09:12 am
- Apricus Biosciences Appoints Manufacturer For Vitaros®, Its Newly Approved Drug To Treat Erectile Dysfunction In Canada - Business Wire 12.01.10 | 10:12 am
- Apricus Biosciences Announces New NexACT® Transbuccal Delivery Data Published In The International Journal Of Pharmaceutics - Business Wire 11.29.10 | 10:11 am
- Apricus Biosciences Files Phase 3 Registration Protocol For PrevOnco™ For Special Protocol Assessment Consideration By The FDA - Business Wire 11.22.10 | 10:11 am
- Apricus Bio Announces Pre-Clinical Data Showing Significant Improvement In Solubility And Absorption Of NexACT®-Based Small Molecule Drugs Selected From The Biopharmaceutics Classification System - Business Wire 11.19.10 | 10:11 am
- Apricus Biosciences’ CEO Bassam Damaj, Ph.D., Interviewed By The Financial Network CDTV.net - Business Wire 11.17.10 | 10:11 am
- Apricus Biosciences Receives Canadian Approval For Vitaros® As First Line Therapy For Erectile Dysfunction - Business Wire 11.15.10 | 12:11 pm
- Apricus Biosciences Announces 2010 Third Quarter Financial Results Conference Call - Business Wire 11.10.10 | 10:11 am
Partner Headlines for APRI
- Smart Stocks Watch: Apricus Biosciences - Seeking Alpha 09.21.12 | 09:09 am
- Apricus, Takeda Ink Marketing Deal - Analyst Blog - NASDAQ 09.14.12 | 10:09 pm
- Apricus, Takeda Ink Marketing Deal - Analyst Blog - Zacks 09.14.12 | 06:09 pm
- Tesaro Initiated at OUTPERFORM and 2 Initiated Shares on the Move - Wall St. Cheat Sheet 07.23.12 | 04:07 am
- REVEALED: New Stock Analyst Coverage to Evaluate - Wall St. Cheat Sheet 06.14.12 | 03:06 am
- Apricus Biosciences Strengthens Vitaros and Nexact Patent Estate With Two New Patent Allowances - Benzinga 05.25.12 | 01:05 pm
- Apricus Biosciences Granted Regulatory Meeting With FDA for Femprox(R) for the Treatment of Female Sexual Arousal Disorder - Benzinga 05.21.12 | 09:05 am
- Health Canada Grants Apricus Biosciences Pre-NDS Meeting for MycoVa(TM) for the Treatment of Onychomycosis - Benzinga 05.11.12 | 09:05 am
- Apricus Biosciences; Vitaros Has Great Potential - Seeking Alpha 04.22.12 | 09:04 am
- Apricus Biosciences and Elis Pharma Sign License Agreement for MycoVa in the Middle East and the Gulf - Benzinga 01.10.12 | 09:01 am
